Introduction
============

Osteoarthritis (OA) is an emerging global health burden prevalent among aging populations ([@ref-29]; [@ref-26]). OA is caused by cartilage matrix degradation, chondrocyte death, and osteophyte formation ([@ref-16]; [@ref-8]). The pathology of OA is fairly well understood and multiple therapies exist to treat patient symptoms. These include corticosteroids and nonsteroidal anti-inflammatory drugs ([@ref-6]; [@ref-4]), experimental stem cell therapies to treat specific forms of OA, and biologics to address specific inflammatory mediators, such as cytokines. OA is also commonly treated with joint replacement surgery. However, there is continued desire to find new therapeutic targets to improve osteoarthritis treatment.

Recent studies have evaluated the gene regulation capabilities of long noncoding ribonucleic acids (lncRNAs) in OA development. LncRNAs are non-protein-coding transcripts (\>200 nucleotides) that participate in numerous pathological and physiological processes ([@ref-15]; [@ref-42]; [@ref-30]). Some lncRNAs have been defined as key regulators in the onset and development of OA ([@ref-45]; [@ref-31]; [@ref-39]; [@ref-36]; [@ref-23]; [@ref-37]). For instance, overexpression of HOTAIR may contribute to OA development by inducing chondrocyte apoptosis ([@ref-45]; [@ref-44]). [@ref-13] used microarray and bioinformatics to identify 4,714 lncRNAs differentially expressed in knee cartilage from OA and non-OA patients. Additionally, [@ref-23] used microarrays to identify 153 lncRNAs differentiallly expressed in OA patients and designated a specific lncRNA CIR as critical to degradation of the chondrocyte matrix. Differences in lncRNA expression are often attributed to physiological processes that arise in laboratories using high-throughput screening. To address the lack of information about the role of lncRNAs in the pathogenesis of OA, we used high-throughput microarray to measure differentially expressed lncRNAs and mRNAs from the human knee cartilage of OA patients and non-OA patients.

Materials and Methods
=====================

Specimen collection
-------------------

A Kellgren-Lawrence (KL) system was used to measure OA severity in patients ([@ref-25]). OA cartilage (KL grades 3 or 4) was collected from 34 patients undergoing total knee joint replacement due to severe OA. Normal cartilage (KL grades 0) was collected from 19 patients without history of rheumatoid arthritis or OA (who were being treated for trauma, *thromboangiities obliterans,* osteosarcoma, or limb amputation). Informed consent was signed by all patients and additional informed consent was obtained for publication of subject age and sex. This study was approved by the Ethics Commission of the 163rd Central Hospital of the Chinese People's Liberation Army (IRB. \[2015\] 001). Patient data appears in [Table S1](#supp-7){ref-type="supplementary-material"}. Clinical specimens were divided for qPCR and for array analyses.

LncRNA and mRNA microarray analysis
-----------------------------------

Quality testing, sample labeling, and hybridization to human WT lncRNA microarray (Affymetrix) were conducted by Oebiotech Co (Shanghai, China) ([Fig. S1](#supp-1){ref-type="supplementary-material"}); their detailed protocol can be found in previous publications ([@ref-22]; [@ref-28]). All RNA integrity number (RIN) values were \>7, and 260:280 ratios were \>1.7 (as measured by NanoDrop). The Genechip included 63,542 non-coding and 27,134 coding transcripts. Images were taken with an Affymetrix Scanner3000, and data normalization and probe filtering were conducted using an Affymetrix GeneChip Expression Console (version 4.0; Affymetrix). The lncRNA-mRNA expression between OA and non-OA groups was identified as a ≥2.0 fold-change (FC) for up-regulation or a ≤ − 2.0 fold-change for down-regulation, with *p* ≤ 0.05. Afterwards, GO and KEGG analyses were used to identify roles of differentially expressed mRNAs with respect to GO terms or pathways. Their detailed definitions can be found in previous publications ([@ref-17]; [@ref-41]).

A volcano plot and hierarchical clustering were created to show distinctions in gene expression patterns among samples. Finally, a coding-non-coding gene co-expression (CNC) network was drawn using Cytoscape software. The microarray data are available through the GEO database with the accession number [GSE113825](GSE113825).

RNA extraction and quantitative PCR
-----------------------------------

A RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden, Germany) was used to extract total RNA from tissues according to the manufacturer's directions. A NanoDrop ND-1000 spectrophotometer was used to measure RNA quality and purity. Then SDS-PAGE was used to measure RNA integrity. Total RNA from samples was reverse transcribed into cDNA using an All-in-one First-Strand cDNA Synthesis Kit (GeneCopoeia Inc, Rockville, MD, USA) as directed by the user manual. qPCR primers were designed and synthesized at the Shanghai Sangon Company ([Table S2](#supp-8){ref-type="supplementary-material"}); qPCR was conducted using AceQ qPCR SYBR Green Master Mix (Vazyme Biotech Co, Jiangsu Sheng, China) on a Bio-Rad CFX ConnectTM Real-Time PCR detection system (Bio-Rad, Munchen, Germany) using 10 µl SYBR Master Mix, 0.4 µl forward primer (10 µM), 0.4 µl reverse primer (10 µM), 0.4 µl ROX Reference Dye 1, two µl cDNA, and 6.8 µl MiliQ water. The qPCR reaction conditions were as follows: pre-denaturation at 95 °C for 5 min, followed by 95 °C for 10 s, and 60 °C for 30 s for 40 cycles, and a final extension at 95 °C for 15 s, 60 °C for 60 s, and 95 °C for 15 s. The 2^−ΔΔCt^ method was employed to assess gene expression, as described in previous studies ([@ref-24]). Each experiment was conducted in triplicate.

Cell culture and treatment
--------------------------

Human primary chondrocytes were procured from CHI Scientific, Inc (China). The cells were incubated in DMEM (Gibco, Waltham, MA, USA) medium supplemented with 14% FBS (Gibco, USA) in 6-well culture plates (6 × 10^5^∕well). Cell cultures were cultivated at 37 °C in a 5% CO~2~ incubator and the medium was changed every three days. All studies were conducted using primary chondrocytes from passages 1-4. Cells were treated either with or without 10 ng/ml human recombinant interleukin-1 beta (IL-1 β) (Sigma-Aldrich, St Louis, MO, Germany) for 12 h, 24 h and 48 h.

Cell transfection
-----------------

The overexpression vector, lnc-SAMD14-4(pcDNA3.1^+^-lnc-SAMD14-4), and blank vector, pcDNA3.1(pcDNA3.1^+^- vector), were designed by and purchased from GeneChem Co., Ltd. (Shanghai, China). The vectors were transfected into human primary chondrocytes using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA). Three targeting siRNA, including si-lnc-SAMD14-4 (1\#, 2\# and 3\#), and a control siRNA were designed and purchased from Ribo Biotechnology Co. Ltd. (Guangdong, China). These siRNA (100nM/well) were transfected into human primary chondrocytes to assess gain or loss of function of lnc-SAMD14-4.

Statistical analysis
--------------------

Differences in expression of lncRNA-mRNA between OA and non-OA groups were assessed with a Student's *t* test. GO and KEGG pathways were assessed using Fisher's exact test. Other data were analyzed using one-way ANOVA and multiple groups were compared using Bonferroni's method. GraphPad Prism 6.0 (GraphPad Software San Diego, CA) was applied for data analysis and drawing. Data are shown as means ± SD, and *p* \< 0.05 was considered statistically significant.

Results
=======

Analysis of differential expression among lncRNAs-mRNAs in OA
-------------------------------------------------------------

We found 2,042 lncRNAs differed significantly in expression levels between OA and non-OA tissue ([Table S3](#supp-9){ref-type="supplementary-material"}). The most upregulated lncRNA was lnc-SAMD14-4 and the most downregulated lncRNA was lnc-MSMP-2. The 15 most dysregulated (either down or up) lncRNAs are listed in [Table 1](#table-1){ref-type="table"}.
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###### Most regulated lncRNAs.
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  **GeneSymbol**   **Regulation**   **Type**    **Fold change(abs)**   *P*-**value**
  ---------------- ---------------- ----------- ---------------------- ---------------
  lnc-SAMD14-4     Up               Exonic      86.11047               0.00036
  lnc-MARCKS-7     Up               -------     80.51785               0.0000923
  lnc-SAMD14-5     Up               Exonic      76.39162               0.0000161
  lnc-AP3S2-2      Up               Exonic      57.44485               0.001265177
  lnc-CASD1-2      Up               Exonic      56.14244               0.001261528
  lnc-TSPAN13-4    Up               Exonic      50.915787              0.00000633
  lnc-PPM1N-1      Up               Exonic      47.80361               0.009312962
  lnc-TRPC4-2      Up               Exonic      47.43022               0.009825662
  lnc-C1orf196-1   Up               Linc        40.125366              0.0000202
  lnc-SMAD5-7      Up               Exonic      39.585285              0.022567188
  lnc-TSPAN13-5    Up               Exonic      37.4391                0.00000077
  lnc-SFRP1-2      Up               Exonic      36.96935               0.001035282
  lnc-HJURP-12     Up               Exonic      36.914413              0.000862
  lnc-TEX2-2       Up               Exonic      33.92366               0.000572
  lnc-MS4A6E-1     Up               Exonic      31.000843              0.001087416
  lnc-MSMP-2       Down             Exonic      22.78652               0.030858
  lnc-NPVF-4       Down             Linc        18.66038               0.0000169
  lnc-CBLL1-4      Down             Exonic      14.84985               0.022533
  MLLT4-AS1        Down             -------     12.8248                0.002052
  lnc-NPVF-10      Down             -------     12.68418               0.0000278
  lnc-ASZ1-3       Down             Exonic      11.32834               0.000425
  SAMD12           Down             -------     9.023141               0.006789
  lnc-NPVF-5       Down             -------     9.018275               0.000095
  lnc-IRGM-3       Down             Exonic      8.909008               0.001227
  lnc-ERCC5-4      Down             Linc        8.883492               0.000686
  lnc-SSR3-6       Down                         8.876818               0.000349
  lnc-DLGAP1-9     Down             Exonic      8.776601               0.001021
  lnc-SSR3-5       Down             Antisense   8.354682               0.000208
  lnc-CHI3L1-1     Down             Exonic      8.350381               0.011126
  lnc-OXNAD1-6     Down             Antisense   8.14148                0.0000128

mRNA expression data revealed dysregulation of 2,011 mRNAs in OA cartilage tissue, as compared to non-OA cartilage tissue; it was found that 1,386 mRNA were upregulated and 625 mRNAs were downregulated ([Table S4](#supp-10){ref-type="supplementary-material"}). Among these mRNAs, the most upregulated protein coding RNA was MMP-13, which is responsible for regulating articular cartilage degradation ([@ref-10]). MYOC was the most strongly down-regulated. The top 15 upregulated and downregulated mRNAs appear in [Table 2](#table-2){ref-type="table"}. Data on differentially expressed genes (including lncRNA and mRNA) appear in [Figs. 1A](#fig-1){ref-type="fig"}--[1C](#fig-1){ref-type="fig"}.
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###### Most regulated mRNAs in this study.
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  **GeneSymbol**   **Regulation**   **Fold change(abs)**   *P*-value
  ---------------- ---------------- ---------------------- -------------
  MMP13            Up               272.535                0.000564
  SERPINF1         Up               191.17508              0.000000141
  COL1A1           Up               175.43033              0.0000199
  POSTN            Up               156.12422              0.008303139
  LRRC15           Up               105.57993              0.000129
  COL1A2           Up               85.32694               0.000776
  THBS2            Up               74.47372               0.002686227
  FNDC1            Up               72.167336              0.001257106
  RP11-429G19.3    Up               69.320656              0.000105
  MS4A4A           Up               64.19533               0.000564
  FPR3             Up               56.89943               0.0000552
  MSR1             Up               53.758953              0.000178
  AHR              Up               52.798218              0.0000266
  TNFAIP6          Up               51.144848              0.018054951
  PLXDC1           Up               51.0092                0.00043
  MYOC             Down             49.693558              0.008422094
  PAK3             Down             35.395626              0.014492353
  APOD             Down             26.913952              0.011042964
  MSMP             Down             24.774714              0.036745384
  SLC26A4          Down             20.350153              0.024579711
  AC003090.1       Down             19.897524              0.0001
  CYP4F11          Down             12.0151615             0.001603253
  CTTNBP2          Down             11.738498              0.000434
  ABCA5            Down             10.876956              0.000144
  ZMAT1            Down             9.586397               0.000137

![Volcano plot and hierarchical clustering of lncRNA and mRNA differential expression profiles between non-OA and OA groups for 10 cartilage tissues.\
(A) Volcano plot of dysregulated lncRNA and mRNA (dots denotes gene). Grey spots represent *p* \> 0.05; green spots represent *p* \< 0.05 and fold-change \<2. Red spots represent up-regulated genes (*p* \< 0.05 and fold-change \>2.0), and blue spots represent up-regulated genes (*p* \< 0.05 and fold-change \< − 2.0). Heatmap of differentially expressed lncRNA (B) and mRNA (C). Colors denote relative expression: red represents high relative expression; green represents low relative expression.](peerj-07-7491-g001){#fig-1}

Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of dysregulated mRNAs
-------------------------------------------------------------------------------------------------------------

The most enriched GOs targeted by upregulated mRNAs were extracellular matrix organization (GO:0030198), extracellular exosome (GO:0070062), and collagen binding (GO:0005518) in biological process, cellular process, and molecular function ([Figs. 2A](#fig-2){ref-type="fig"}--[2C](#fig-2){ref-type="fig"}, [Tables S5](#supp-10){ref-type="supplementary-material"}--[S7](#supp-13){ref-type="supplementary-material"}). Protein stabilization (GO:0050821), cilium (GO:0005929), and heparan sulfate proteoglycan binding (GO:0043395) were the most enriched GO pathways associated with downregulated transcripts ([Figs. 2D](#fig-2){ref-type="fig"}--[2F](#fig-2){ref-type="fig"}, [Tables S8](#supp-14){ref-type="supplementary-material"}--[S10](#supp-16){ref-type="supplementary-material"}).

![Go analysis of abnormal mRNAs between OA and non-OA groups.\
Enriched Go terms targeted by up-regulated mRNAs (A--C) and down-regulated mRNAs (D--F) according to biological processes, cell components, and molecular function (*p* \< 0.05 as statistically significant according to a Fisher's exact test).](peerj-07-7491-g002){#fig-2}

We identified 27 pathways with upregulated mRNAs and the most enriched pathway was cytochrome P450 ([Table S11](#supp-17){ref-type="supplementary-material"}). Additionally, 94 pathways corresponded to downregulated mRNAs, according to KEGG pathway analysis, and the top enriched pathway was focal adhesion ([Table S12](#supp-18){ref-type="supplementary-material"}). The top 20 pathways enriched by downregulated and upregulated transcripts appear in [Figs 3A](#fig-3){ref-type="fig"} and [3B](#fig-3){ref-type="fig"}.

![KEGG pathway analysis of abnormal mRNAs between OA and non-OA groups.\
The top 20 pathways targeted by down-regulated (A) and up-regulated (B) transcripts (*p* \< 0.05 was statistically significant according to a Fisher's exact test).](peerj-07-7491-g003){#fig-3}

LncRNA-mRNA co-expression network
---------------------------------

Co-expression networks are of biological interest because co-expressed genes are controlled by the same transcriptional regulatory program, are functionally related, or are members of the same pathway or protein complex ([@ref-43]; [@ref-38]). It has been confirmed that apoptosis is involved in OA pathogenesis ([@ref-46]; [@ref-18]; [@ref-2]; [@ref-21]), and that the PI3K-Akt signaling pathway is important for apoptosis ([@ref-11]). We analyzed the 74 dysregulated mRNAs found to be enriched in the PI3K-Akt signaling pathway ([Table S13](#supp-19){ref-type="supplementary-material"}) and identified 1,974 correlations for lncRNA-mRNA interaction pairs that satisfy *p* \< 0.01 and Pearson correlation coefficients\>0.95 ([Table S14](#supp-20){ref-type="supplementary-material"}). Then, the top 500 of 1,974 lncRNA-mRNA pairs were used to draw the network ([Table S15](#supp-21){ref-type="supplementary-material"}). Of the top 500 lncRNA-mRNA pairs, which included 57 mRNAs and 363 lncRNAs, 362 pairs had a positive association; the rest were negatively associated. It appears that a single mRNA may pair with multiple lncRNAs while most lncRNAs may only pair with a single mRNA ([Fig. 4](#fig-4){ref-type="fig"}). Some lncRNA-mRNA pairs included the most dysregulated mRNA and lncRNA. For example, *COL1A1* (mRNA, FC = 175.43) and *COL1A2* (mRNA, FC = 85.32) were strongly associated with lnc-SAMD14-4 (lncRNA, FC = 86.11). All lncRNA-mRNA co-expressed pairs had Pearson correlation coefficients\>0.98

![LncRNA-mRNA co-expression network.\
Green node represents mRNA; red node represents lncRNA. Line indicates a co-expression relationship between lncRNA-mRNA. The node degree is indicated by the node size.](peerj-07-7491-g004){#fig-4}

Verification of lncRNAs and mRNAs expression by qRT-PCR
-------------------------------------------------------

To confirm microarray profiling analysis, four lncRNAs (lnc-SAMD14-4, lnc-MARCKS-7, lnc-MSMP-2 and lnc-NPVF-4) and four mRNAs (*SERPINF1*, *COL1A1*, *MYOC* and *PAK3*) were selected and measured using qRT-PCR in 53 clinical specimens (34 OA and 19 non-OA specimens). The results from the qRT-PCR agreed with chip profiling analysis ([Fig. 5](#fig-5){ref-type="fig"}).

![qPCR and microarray data.\
Values are means + SD (*n* = 53), and \* *p* \< 0.05 was statistically significant compared to the non-OA group.](peerj-07-7491-g005){#fig-5}

Prediction of novel lncRNA targeting
------------------------------------

We studied the most dysregulated lncRNA, lnc-SAMD14-4, for its potential function in OA development. To analyze the gene coding-potential of lnc-SAMD14-4, the open-reading frames (ORFs) and codon-substitution frequency (CSF) were measured according to former research protocol ([@ref-23]; [@ref-32]). The ORF Finder (National Center for Biotechnology Information) failed to predict ORFs more than 300 nt. Furthermore, BLAST search of all the positive-sense strand ORFs, which are marked by " +" in [Fig. S2](#supp-3){ref-type="supplementary-material"}, yielded no highly homologous protein among short peptides. Alternatively, PhyloCSF analysis of lnc-SAMD14-4 was negative ([Fig. S3](#supp-4){ref-type="supplementary-material"}). These results confirmed that lnc-SAMD14-4 does not encode any functional protein product.

*COL1A1*, *COL1A2* and lnc-SAMD14-4 were highly expressed in the IL-1 β-treated human primary chondrocytes
----------------------------------------------------------------------------------------------------------

According to our co-expression network analysis, *COL1A1* and *COL1A2* were strongly associated with lnc-SAMD14-4. Thus, we speculated that lnc-SAMD14-4 may contribute to OA by interacting with *COL1A1* and *COL1A2*. Previous studies have used human primary chondrocytes treated with IL-1 β-treated to model the process of human osteoarthritis ([@ref-13]; [@ref-14]). We determined expression levels of *COL1A1*, *COL1A2* and lnc-SAMD14-4 by qPCR. We found that *COL1A1* and *COL1A2* were upregulated after human chondrocytes were treated with IL-1 β for 24 h and 48 h. Furthermore, upregulation of lnc-SAMD14-4 with IL-1 β treatment was time-dependent ([Fig. 6](#fig-6){ref-type="fig"}). These results suggest a positive correlation between lnc-SAMD14-4 and *COL1A1*, *COL1A2* expression induced by IL-1 β treatment. Hence, human primary chondrocytes were treated either with or without IL-1 β for 48 h in the follow-up experiments.

![The mRNA levels of *COL1A1* (A), *COL1A2* (B) and lnc-SAMD14-4 (C) were detected by QPCR in the IL-1 β-treated human primary chondrocytes.\
The mRNA expression was normalized to GAPDH expression and conversion by 2^−ΔΔCt^. Values are means + SD (*n* = 3). Data were analyzed using one-way ANOVA followed by Dunnett-*t*test.](peerj-07-7491-g006){#fig-6}

lnc-SAMD14-4 was involved in IL-1 β-induced *COL1A1* and *COL1A2* expression in human primary chondrocytes
----------------------------------------------------------------------------------------------------------

To further explore the function of lnc-SAMD14-4 in eliciting IL-1 β-induced *COL1A1* and *COL1A2* expression, we performed gain/loss of function experiments. We confirmed that lnc-SAMD14-4 expression in human primary chondrocytes increased after pcDNA3.1^+^- lnc-SAMD14-4 transfection ([Fig. S4](#supp-5){ref-type="supplementary-material"}). Additionally, as shown in [Fig. 7](#fig-7){ref-type="fig"}, lnc-SAMD14-4 overexpression promoted expression of *COL1A1* and *COL1A2* in the human primary chondrocytes, regardless of treatment with IL-1 β (*p* \< 0.05).

![Effects of lnc-SAMD14-4 overexpression on the relative expression levels of *COL1A1* (A), *COL1A2* (B) in IL-1 β-treated human primary chondrocytes detected by QPCR.\
Data were analyzed using one-way ANOVA followed by Dunnett-*t*test.](peerj-07-7491-g007){#fig-7}

To explore the knockdown effects of lnc-SAMD14-4 on *COL1A1* and *COL1A2*, we designed and transfected three independent si-lnc-SAMD14-4 (1\#, 2\# and 3\#) in human primary chondrocytes. The strongest silencing effects were observed in si-lnc-SAMD14-4 (2\#), which was used for silencing in subsequent experiments ([Fig. S5](#supp-6){ref-type="supplementary-material"}). The knockdown of lnc-SAMD14-4 significantly decreased the expression of *COL1A1* and *COL1A2* in human primary chondrocytes, regardless of treatment with IL-1 β-treatment ([Fig. 8](#fig-8){ref-type="fig"}).

![Effects of lnc-SAMD14-4 suppression on the relative expression levels of *COL1A1* (A), *COL1A2* (B) in IL-1 β-treated human primary chondrocytes detected by QPCR.\
Data were analyzed using one-way ANOVA followed by Dunnett-*t*test.](peerj-07-7491-g008){#fig-8}

Discussion
==========

To our knowledge, there has been some study focusing on the lncRNA expression profiles in osteoarthritis (OA). For instance, Fu et al. identified 4,714 lncRNAs and Liu et al. identified 152 lncRNAs that were differentially expressed in OA cartilage as compared to non-OA cartilage Pearson's group treated primary chondrocytes isolated from hip articular cartilage with IL-1 β to stimulate OA. This led them to identify lncRNAs related to the inflammatory response in human hip OA cartilage ([@ref-31]; [@ref-13]). However, there was much left to learn regarding the roles of lncRNAs in osteoarthritis.

In the present study, we analyzed human knee cartilage from OA and non-OA patients by measuring expression profiles of lncRNAs and mRNAs using high-throughput microarray and bioinformatics. For this, we used a standards filter of FC ≥2.0, *p* \< 0.05. An important point to note is that our work used Affymetrix and previous studies used Arraystar, which is a different platform. This was problematic when comparing lncRNA data.

Using these chips, we identified 2,042 dysregulated lncRNAs and 2,011 differentially expressed mRNAs in OA samples as compared to non-OA tissues. These included *COL1A1, COL1A2, MMP-13*, *MMP-9*, and *TNFAIP6*, which are associated with cartilage biology and OA ([@ref-12]; [@ref-3]; [@ref-1]; [@ref-33]; [@ref-35]). Excluding *MMP13* mRNA from the study (which has already been linked to chondrocyte biological processes and osteoarthritis ([@ref-10])), studies with the top four dysregulated lncRNAs and mRNAs verified that qRT-PCR data for 53 specimens (34 OA and 19 normal specimens) were consistent with chip analysis.

Next, GO analysis and pathway analysis analyzed the biological function enrichment of differentially expressed mRNA. For instance, the most enriched GO terms targeted by up-regulated mRNAs were extracellular matrix organization (GO:0030198), extracellular exosome (GO:0070062), and collagen binding (GO:0005518) in biological processes, cellular processes, and molecular function. Functions of the extracellular matrix and collagen binding have been accepted as important to the onset and progression of OA ([@ref-40]; [@ref-5]).

A lncRNA-mRNA co-expression network was constructed to identify associations between lncRNAs and mRNAs. The fundamental principle of co-expression network analysis is that opposite or identical expression pattern of mRNAs and lncRNAs indicate some interaction between the lncRNA-mRNA. We noticed that most dysregulated lncRNA or mRNA made lncRNA-mRNA pairs. Among these, lnc-SAMD14-4 (lncRNA, FC = 86.11) was strongly associated with *COL1A1* (mRNA, FC = 175.43) and *COL1A2* (mRNA, FC = 85.32). Type I collagen is a triple helix consisting of two pro-alpha1(I) chains encoded by two *COL1A1* genes and one pro-alpha2(I) chain encoded by one *COL1A2* gene. Type I collagen is the most abundant collagen of the human body present in scar tissue and it is also regarded as the end product when tissue heals ([@ref-19]). It is reported that Type I collagen is rare in normal chondrocytes, however, higher levels of Type I collagen was detected in osteoarthritis cartilage, particularly in late stages of osteoarthritis ([@ref-27]).

It is reasonable to suggest that lnc-SAMD14-4 may promote expression of the *COL1A1* gene and *COL1A2* gene, thereby contributing to the pathogenesis of OA. To verify this hypothesis, Il-1 β-treated human chondrocytes were used to imitate the genetic change associated with osteoarthritis development, as uncovered in previous studies ([@ref-13]; [@ref-34]). Our study suggested a positive correlation between expression of lnc-SAMD14-4 and *COL1A1* gene and *COL1A2* gene in Il-1 β-treated human chondrocytes. This is consistent with expression patterns found in cartilage from osteoarthritis patients. Thus, lnc-SAMD14-4 may play a key role in the pathogenesis of osteoarthritis by promoting the expression of the *COL1A1* and *COL1A2* genes.

Age is the highest risk factor for the pathogenesis of osteoarthritis. This link between aging and OA is complex, but there are some common physical mechanisms in aging and OA. One limitation of this study is the lack of age-matched patients. In clinical practice, the age of OA patients was usually older than the age of non-OA patients. However, some of the most dysregulated mRNAs in our study, including MMP-13 and POSTN, were OA-related ([@ref-7]; [@ref-9]; [@ref-20]), which suggests that the differences observed in our arrays were at least in part a consequence of OA. Therefore, further research should be performed with age-matched patients or a more ideal model in the future.

Conclusion
==========

Taken together, the Affymetrix chips and bioinformatics methods were combined to explore differential expression of lncRNAs from OA articular cartilage and non-OA articular cartilage. This study revealed that lnc-SAMD14-4 may upregulate the *COL1A1* and *COL1A2* genes, contributing to the pathogenesis of OA. This provides a potential therapeutic target for treatment.
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###### The quality control of total RNA
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###### QPCR analysis confirmed increased lnc-SAMD14-4 expression in human primary chondrocytes after pcDNA3.1 ^+^-lnc-SAMD14-4 transfection

QPCR analysis confirmed increased lnc-SAMD14-4 expression in human primary chondrocytes after pcDNA 3.1^+^-lnc-SAMD14-4 transfection.

###### 

Click here for additional data file.

10.7717/peerj.7491/supp-6
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###### The cellular process of Go enrichment analysis for up-regulated mRNA in OA and non-OA groups

###### 

Click here for additional data file.

10.7717/peerj.7491/supp-13

###### Molecular functions for Go enrichment analysis of up-regulated mRNA in OA and non-OA groups
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###### Cellular process for GO enrichment analysis of down-regulated mRNA in OA and non-OA groups
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